When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
Before Congress adjourned for Christmas, congressional leadership had set ambitious goals to counter the Chinese Communist ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
The transaction – announced on Christmas Eve – comes after WuXi AppTec has been thrust into the US political spotlight as a ...
China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...
GlobalData on MSN2d
WuXi Biologics to sell Ireland-based vaccine site to MSD for $500mThe transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.
Chinese cybersecurity regulator details on the lenient certification method for cross-border data transfer; U.S. issues final ...
In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...
2024 was eventful in the life sciences space – and key trends are expected to continue in the new year. Below, we outline key areas to watch in 2025. In recent years, several trends have heightened ...
A summary of recent health news includes Louisiana's first bird flu death, WuXi Biologics' sale of an Irish facility to Merck ...
Market capitalization of the largest public biotech companies jumps nearly 12% year-over-year, as all but five of them show ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback